Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06358040
Other study ID # 2023-0328
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date July 2025

Study information

Verified date April 2024
Source Hospital for Special Surgery, New York
Contact William Chan, MEng
Phone 917-260-4788
Email chanw@hss.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The opioid crisis continues to plague the United States. While great strides have been made nationwide to decrease overprescribing, improvements are still needed to appropriately educate patients on the safe and responsible use, storage and disposal of opioids. Pain after surgery is often treated with opioid medications. Opioid medications can have side effects. Some side effects are relatively minor (constipation, nausea, vomiting), while others are more severe (sedation, abnormal breathing, etc.) and can lead to serious illness or death. Opioid pain medications when used the wrong way may also be addictive. Due to theses side effects, sometimes patients feel uncomfortable about taking these medications, and doctors prescribe them very cautiously. However, when used properly and safely, opioid pain medications are excellent pain relievers. Addinex, a technology company, has developed a device to help patients take opioids more safely. In this study the investigators aim to enroll a total of 30 patients who undergo spine surgery. Half will be randomly assigned to receive a standard pill bottle with opioids at discharge and will download a mobile app so that they can record their daily pain scores and the number of opioids they take for two weeks after surgery. The other half will receive the new opioid dispenser filled with opioids and a mobile app that generates a passcode that opens that device only at designated times. For this group of patients, every time the patient wants to take an opioid, they need to go to the app, enter their pain score before the app generates a passcode. The investigators will be tracking all study patients' opioid use and pain scores for the two weeks after surgery, will count how many pills they have left over 14 days after their surgery during a live telehealth session, and ask patients how they liked using the device. Results from this study will help understand if the Addinex device could potentially be useful to patients in the future after surgeries as opposed to typical pill bottles.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date July 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - opioid-naive patients or intermittent opioid users within 3 months of scheduled surgery - At least 18 years old - presenting for primary elective one-level lumbar laminectomy and/or discectomy via posterior approach with participating surgeon - planned discharge on day of surgery/23 hour admission - planned discharge to home Exclusion Criteria: - patients with opioid-tolerance - patients without a smart-phone or without the ability to perform Telehealth visits - patients unable to utilize the medication dispensing device - patients presenting for other surgeries/surgeries with combined anterior/lateral approaches - patient refusal - allergy or intolerance to opioids - planned admission after surgery - planned discharge disposition to nursing facility or skilled rehabilitation - planned use of or preference for opioid other than oxycodone - patients who are pregnant

Study Design


Intervention

Device:
Opioid-Dispensing Device
Addinex Opioid-Dispensing Device
Other:
App
Addinex App
Standard Opioid Pill Bottle
Standard Opioid Pill Bottle

Locations

Country Name City State
United States Hospital for Special Surgery New York New York

Sponsors (1)

Lead Sponsor Collaborator
Hospital for Special Surgery, New York

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative Opioid Consumption at Postoperative Day 14 (POD14) Cumulative Opioid Consumption at Postoperative Day 14 (POD14) following lumbar decompression (microdiscectomy/laminectomy), expressed as number of tablets and morphine equivalents (MED in mg) and collected via app starting at discharge to 14 days later. Hospital Discharge to Postoperative Day 14
Secondary NRS pain intensity ratings Numerical Rating Scale (NRS) Pain Intensity Ratings from 0-10, with 0 being no pain at all to 10 being the worst pain imaginable: patient-reported in app PACU; Daily after Hospital Discharge: Postoperative Day 1 up to Postoperative Day 14
Secondary Patient satisfaction with the app and with the dispensing device On a scale of 0-10 (0 being completely dissatisfied, 10 being completely satisfied), how satisfied are you with the app? On a scale of 0-10 (0 being completely dissatisfied, 10 being completely satisfied), how satisfied are you with the device? Postoperative Day 14
Secondary Frequency of reported difficulties using the device Frequency of reported difficulties using the device assessed via initiation of patient call to study team; activation of device unlocking mechanism. Daily up to Postoperative Day 14
Secondary Frequency of reported difficulties using the app Frequency of reported difficulties using the app assessed via initiation of patient call/email to study team. Daily up to Postoperative Day 14
Secondary Opioid prescription refill rates Opioid prescription refill rates using electronic health records 6 weeks postoperatively
Secondary Concordance of app data and medication left in the device or pill bottle (medication reconciliation) At Postoperative Day 14, the number of pills consumed as documented via the app, compared to actual pills left over in the device/pill bottle (telemedicine medication reconciliation). Postoperative Day 14
See also
  Status Clinical Trial Phase
Completed NCT05480111 - The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy Phase 4
Completed NCT06129305 - Erector Spina Muscle Distance From the Skin at Different Thoracal Elevations
Completed NCT04401826 - Micro-surgical Treatment of Gummy Smile N/A
Recruiting NCT04020133 - the Role of Popliteal Plexus Block in Pain Management After Anterior Cruciate Ligament Reconstruction. N/A
Completed NCT03023462 - Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair N/A
Completed NCT03546738 - Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery N/A
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Terminated NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Completed NCT02525133 - Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Phase 3
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Enrolling by invitation NCT05316168 - Post Operative Pain Management for ACL Reconstruction Phase 3
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Enrolling by invitation NCT04574791 - Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty N/A
Completed NCT04073069 - Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults Phase 4
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Recruiting NCT05351229 - Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery Phase 4
Enrolling by invitation NCT05543109 - Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block N/A
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04919317 - Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty Phase 2